Alto Neuroscience (NYSE:ANRO) Price Target Cut to $44.00 by Analysts at JonesTrading

Alto Neuroscience (NYSE:ANRO) had its target price reduced by equities researchers at JonesTrading from $49.00 to $44.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. JonesTrading’s price target indicates a potential upside of 102.48% from the company’s previous close.

Other research analysts also recently issued research reports about the company. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Wedbush reduced their price objective on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Robert W. Baird upped their target price on shares of Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a report on Wednesday, March 18th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.57.

Alto Neuroscience Stock Performance

Shares of NYSE:ANRO traded down $1.68 during trading on Thursday, hitting $21.73. 285,924 shares of the company were exchanged, compared to its average volume of 248,452. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $25.17. The stock has a 50 day moving average of $19.09 and a 200 day moving average of $14.63. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The company has a market cap of $694.22 million, a PE ratio of -10.14 and a beta of 2.52.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. As a group, equities research analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new stake in Alto Neuroscience during the 1st quarter valued at $52,000. Torren Management LLC bought a new position in shares of Alto Neuroscience during the fourth quarter valued at approximately $62,000. Invesco Ltd. purchased a new stake in Alto Neuroscience in the first quarter worth $67,000. Vanguard Personalized Indexing Management LLC lifted its stake in Alto Neuroscience by 13.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after acquiring an additional 2,055 shares during the period. Finally, Bridgeway Capital Management LLC boosted its holdings in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.